Biofil Chemicals & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 27, 2025
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals Limited submitted the voting results and combined scrutinizer's report for its 40th Annual General Meeting held on September 27, 2025, via video conferencing. Eight resolutions were put to vote, and all were approved by shareholders with the requisite majority. Voting was conducted through remote e-voting and e-voting at the AGM, with L.N. Joshi, Practicing Company Secretary, acting as the scrutinizer. The resolutions covered adoption of audited financial statements for FY ended March 31, 2025, re-appointment of a retiring director, appointment of a secretarial auditor, re-appointment of two independent directors for a second five-year term, approval of material related party transactions with Cyano Pharma Private Limited, change in designation of Mr. Ketan Shah to Chairman and Managing Director, and confirmation of Mr. Smitesh Shah as a promoter non-executive director. Total votes polled were 8,469,916 (about 52% of outstanding shares), with each resolution passing with over 99.98% support.
This is a routine regulatory filing confirming that all AGM resolutions were passed with overwhelming shareholder support, including the re-appointment of independent directors and a key management reshuffle elevating Mr. Ketan Shah to Chairman and Managing Director. No material surprise or dissent is evident, and the stock is unlikely to see significant price movement from this disclosure alone.